Navigation Links
Patients with EGFR exon 20 insertions have poorer prognosis
Date:1/15/2013

DENVER Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in nonsmall-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies. A recent study published in the February 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concludes that patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations, but a poorer prognosis.

Researchers from the Dana-Farber Cancer Institute studied 1,086 patients who underwent EGFR genotyping between 2004 and 2012. No significant differences were identified between the cancers carrying exon 20 insertions and those with the common EGFR mutations. However, cancers with exon 20 insertions were more commonly seen in patients who are never-smokers and in Asian patients. Median survival of patients with exon 20 insertions was 16 months, similar to the survival of wild-type cancers and shorter than the survival of cancers with common EGFR mutations.

Given the findings, the researchers, "estimate that lung cancers with EGFR exon 20 have an annual incidence of approximately 2,000 to 4,000 patients in the United States, not dissimilar from the expected incidence of other uncommon genotype-defined subsets of NSCLC such as those with ROS1 rearrangements, BRAF mutations, or HER2 insertions."

To conclude the researchers say, "previously treated NSCLC carrying EGFR exon 20 insertions represent a population on oncogene-addicted cancers in need of targeted therapy development."


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1

Related biology news :

1. Reproductive health providers should discuss environmental exposure risks with patients
2. Low-calorie diet may be harmful for bowel disease patients
3. Interventional radiology: Mitigating symptoms, improving quality of life of MS patients
4. Interventional radiologists see significant symptom relief in MS patients
5. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
6. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
7. Obese patients face higher radiation exposure from CT scans -- but new technology can help
8. Researchers identified a protein useful in predicting the risk of pulmonary metastases in breast cancer patients
9. Transcatheter aortic valve implantation shows promise in patients with severe aortic stenosis
10. Urgent research needed to determine most effective follow-up care for lung cancer patients
11. Gene signature helps identify risk of relapse in lung cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... compared with fourth quarter of 2014. Gross margin was 46% ... Earnings per share increased to SEK 6.39 (loss: 0.49). ... , --> --> January ... (233.6), up 1,142% compared with 2014. Gross margin was 43% ...
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/1/2016)... -- Rising sales of consumer electronics coupled ... gesture control market size through ... electronics coupled with new technological advancements to drive global ... through 2020   --> Rising ... to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016  CytRx Corporation ... development company specializing in oncology, today announced that ... security agreement with Hercules Technology Growth Capital, Inc. ... $40 million in financing. --> ... first $25 million of financing under the loan ...
(Date:2/8/2016)... Maryland (PRWEB) , ... February 08, 2016 , ... Information ... BSI Web product. The upgrade represents a completely new technical foundation and is ... will offer a responsive design interface, significantly increased speed for search results, a streamlined ...
(Date:2/8/2016)... that its new website has gone live. On Thursday, Feb. 4, the company unveiled a re-envisioned ... Visit the new site: www.diplomat.is ... ... Diplomat Specialty Pharmacy ... "The goal was to reimagine the website and create a smarter, more comprehensive digital platform," said ...
(Date:2/5/2016)... Feb. 5, 2016  In the pharmaceutical industry the ... host of launch activities including the identification and engagement ... activity is especially high in the oncology therapeutic area ... Practices and the Role of Medical Affairs in Oncology ... on oncology therapies find better ways to utilize medical ...
Breaking Biology Technology: